AstraZeneca PLC (AZN)vsCompugen (CGEN)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
CGEN
Compugen
$2.66
+2.31%
HEALTHCARE · Cap: $268.77M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 80625% more annual revenue ($58.74B vs $72.76M). CGEN leads profitability with a 48.6% profit margin vs 17.4%. CGEN appears more attractively valued with a PEG of 1.29. CGEN earns a higher WallStSmart Score of 69/100 (B-).
AZN
Buy64
out of 100
Grade: C+
CGEN
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for CGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 45 in profit
Keeps 49 of every $100 in revenue as profit
Strong operational efficiency at 83.2%
Revenue surging 4477.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 48.6% and operating margin at 83.2%. Revenue growth of 4477.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while CGEN is a growth play — different risk/reward profiles.
CGEN carries more volatility with a beta of 2.77 — expect wider price swings.
CGEN is growing revenue faster at 4477.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
CGEN scores higher overall (69/100 vs 64/100), backed by strong 48.6% margins and 4477.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?